Posttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney Allograft. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Comoli, Patrizia; Quartuccio, Giuseppe; Cioni, Michela; Parodi, Angelica; Nocera, Arcangelo; Basso, Sabrina; Fontana, Iris; Magnasco, Alberto; Sioli, Viviana; Guido, Ilaria; Klersy, Catherine; Zecca, Marco; Cardillo, Massimo; Ghiggeri, Gian Marco; Ginevri, Fabrizio
• Is Part Of: Transplantation. Volume 99:Issue 1(2015)
• Publication Date: 2015-01
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; Transplantation immunology -- Periodicals; 617.95
• DOI: 10.1097/TP.0000000000000276
• Languages: English
• ISSNs: 0041-1337

Abstract

Abstract : Background: Development of de novo donor-specific antibodies (dnDSA) is associated with late or chronic antibody-mediated rejection (CAMR) and poor graft outcome in low-risk kidney transplant recipients. High-level soluble B-cell activating factor (sBAFF) was observed in kidney recipients at higher risk of developing dnDSA. Methods: We longitudinally analyzed sBAFF levels in 81 consecutive primary pediatric kidney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence to gain insight into the events conditioning B-cell activation posttransplant and to analyze the usefulness of paired DSA-sBAFF monitoring in this clinical setting. Results: At a median follow-up of 65 months, 23 patients (28%) developed dnDSA, with 13 of 23 developing CAMR. Irrespective of HLA Ab status, sBAFF levels progressively increased in all patients in the first posttransplant year, thereafter reaching a plateau. sBAFF levels were influenced by the degree of HLA class I antigen match and donor age. Despite higher levels of sBAFF in HLA Ab-positive patients (median and 95% confidence interval sBAFF in DSA+non-DSA patients: 568, 534–608 pg/mL vs. 502, 422–548 pg/mL in Ab-negative patients; P <0.05), we found that sBAFF monitoring could not predict DSA development by a time to event longitudinal analysis. Moreover, sBAFF kinetics up to CAMR onset could not anticipate CAMR development in the DSA cohort. Conclusion: Our findings provide evidence of early posttransplant B-cell activation even in unsensitized recipients of first kidney allograft. The significance of this activation, likely induced by exposition to the allograft, is yet unclear. Abstract : De novo donor-specific antibodies (dnDSA) are linked to more frequent rates of acute and late antibody mediated rejection. Markers or mechanisms on the development of dnDSA remain unknown. This study probes BAFF activation as an early biomarker and its association with de novo donor-specific antibodies.